BioPharmSignal logoBioPharmSignal

Company Profile

Lipocine Inc. Stock Price, News & Catalysts

Ticker:
LPCN
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

2.05 USD (-2.84%)

Close

Last updated: August 17, 2026

18.5M USD

Market cap

Why the stock is moving

As of Aug 17, 2026, LPCN closed down 2.84% at $2.05. No new same-company headline was identified in the current news window.

Company overview

Oral Drug-Delivery Platform

Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.

LPCN 1154

LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future development path uncertain.

Product-Focused Development Model

The company applies its formulation technology to established active pharmaceutical ingredients, seeking differentiated dosing, convenience or pharmacokinetic profiles in endocrine and neuropsychiatric indications.

Future catalysts

    Recent news

    1. 01

      Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

    2. 02

      Lipocine Appoints Michael J. Grissinger to Board of Directors

    3. 03

      Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

    4. 04

      Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

    5. 05

      Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    CORT

    Corcept

    BTTX

    Better Therapeutics

    GLS

    Gelesis

    AXLA

    Axcella

    SGMT

    Sagimet Biosciences

    IGC

    IGC Pharma, Inc.

    MDGL

    Madrigal

    PYPD

    PolyPid

    Frequently Asked Questions

    What is the current stock price of Lipocine Inc. (LPCN)?

    Lipocine Inc. (LPCN) most recently closed at 2.05 USD, a -2.84% move versus the previous session.

    What is the market cap of Lipocine Inc. (LPCN)?

    Lipocine Inc. currently has a market capitalization of 18.5M USD on BioPharmSignal.

    What does Lipocine Inc. do?

    Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth. LPCN 1154 LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future...

    On which exchange is LPCN stock listed?

    Lipocine Inc. (LPCN) is associated with NASDAQ, United States, Biopharma.

    What is Oral?

    Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.

    Which conditions is Lipocine Inc. targeting with Oral?

    Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth. LPCN 1154 LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future...

    What is Drug-Delivery?

    Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.

    What is Platform?

    Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.